Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

NOVABAY PHARMACEUTICALS INC (NBY)

0 + Investors. Track Smart Money conviction in NBY. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +13
Streak
2Q ▲
Buyers last Q
92%

Smart Money Signals — NBY

Based on 26 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added NBY than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
26 hedge funds hold NBY right now — the highest count in 1.8 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +73% more funds vs a year ago

fund count last 6Q
+11 new funds entered over the past year (+73% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 92% buying

23 buying2 selling
Last quarter: 23 funds were net buyers (15 opened a brand new position + 8 added to an existing one). Only 2 were sellers (0 trimmed + 2 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+9 vs last Q)

new funds entering per quarter
Funds opening a new NBY position: 4 → 1 → 6 → 15. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
💰

Value +28595% but shares only +2699% — price-driven

Value
+28595%
Shares
+2699%
Last quarter: the total dollar value of institutional holdings rose +28595%, but actual share count only changed +2699%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

5 → 4 → 1 → 6 → 15 new funds/Q
New funds entering each quarter: 4 → 1 → 6 → 15. A growing number of institutions are discovering NBY each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — NBY

In 2025 Q4, 23 hedge funds were net buyers of NBY (15 opened a new position, 8 added to an existing one), while 2 reduced or exited (2 sold completely) — a 92% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. Net fund flow last quarter: +13 funds (more new holders than closures). Total institutional holders: 26.

Hedge Fund Ownership: NBY

How many hedge funds hold NBY — quarterly history vs. share price
Quarterly hedge fund ownership of NBY vs. share price

Market Analysis: NBY

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: NBY

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy NOVABAY PHARMACEUTICALS INC (NBY) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much NBY has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 63d ago
NBY
-18.8%
XLV
+1288.2%

NBY outperformed XLV by -1307.0% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 18d ago
NBY
-26.2%
XLV
+1.9%

Since the filing became public, NBY outperformed XLV by -28.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

5 top-rated funds 0 high-conviction
Consensus
3.4
/ 10
breadth
×
Elite
0.1
/ 10
conviction
Hedge Fund Positioning: NBY
0 + Investors

Track Smart Money conviction in NBY. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 0 26 -100.0%
13F Shares 0 6M -100.0%
Total Value $0 $83M -100.0%
New Positions 0 15 -15
Increased Positions 0 8 -8
Closed Positions 26 2 +24
Reduced Positions 0 0 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: NBY

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

0 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NBY. Verified SEC 13F-HR filings.

QUARTER:
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — NOVABAY PHARMACEUTICALS INC (NBY)

What does the Smart Money Trend signal show for NBY?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added NBY than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NBY?

More buyers than sellers — 92% buying: Last quarter: 23 funds were net buyers (15 opened a brand new position + 8 added to an existing one). Only 2 were sellers (0 trimmed + 2 sold completely). A clear majority buying is a strong confirmation signal.

Is it too late to buy NOVABAY PHARMACEUTICALS INC (NBY) following the 2026 Q1 hedge fund 13F filings?

As of today, NBY has moved -26.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +1.9% for the XLV sector ETF — an outperformance of -28.1%. Since the quarter end (March 31, 2026), NBY has gained -18.8% vs +1288.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →